Genetic Modification of Primary Chronic Lymphocytic Leukemia Cells with a Lentivirus Expressing CD38

Strategic Insights -

Researchers in Cardiff, UK, have developed a highly efficient method for genetically modifying primary chronic lymphocytic leukemia (CLL) cells using a VSVG pseudotyped lentiviral vector. This technique, detailed in a study published in Haematologica, allows for the introduction and analysis of genes in non-dividing CLL cells. The researchers found that the method was capable of transducing CD38-negative CLL cells with high efficiency, resulting in increased surface CD38 expression in all samples tested.

Key Takeaways:

  • Researchers at Cardiff University developed a lentiviral vector expressing CD38, which was used to genetically modify primary CLL cells with high efficiency.
  • The method caused increased surface CD38 expression in all 17 samples tested, with a mean percentage of positive cells expressing CD38 of 87% (+/-) 8.5%.
  • The mean cell viability was 74% (+/-) 17% after lentiviral transduction.
  • The researchers concluded that the technique should be applicable for the introduction and analysis of other genes in CLL cells.
  • L. Pearce and colleagues are authors of the study, which was published in Haematologica (Pearce et al., 2010).
  • The study highlights the potential of lentiviral vectors for gene therapy in CLL.

Statistics:

  • 17 CLL cell samples were tested for transduction efficiency.
  • The mean percentage of positive cells expressing CD38 was 87% (+/-) 8.5%.
  • The mean cell viability was 74% (+/-) 17% after lentiviral transduction.
  • The study was published in Haematologica, a peer-reviewed journal.

Sources:

  • Pearce, L., et al. (2010). Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38. Haematologica, 95(3), 514-7.
  • Leukemia Gene Therapy (Note: No date provided)